Dear Authors,
If you believe that your paper was mistakenly rejected by other leading journals and you do not agree with final decision, the editors of Reports of Practical Oncology and Radiotherapy offer new fast track review. You may submit your manuscript to Reports of Practical Oncology and Radiotherapy together with all prior peer-reviews obtained from the other journal and your rebuttal letter. We guarantee review based decision within 72 hours from the time we will receive your manuscript.

Fast track submission process: Please submit the manuscript with all reviews and rebuttal letter by email to Dr. Michal Masternak ( for fast review processing. To assure immediate attention the email title must to include: RPOR-fast track- Last Name First Name (of corresponding author).

Volume 12, Number 3, 2007

Efficacy and safety of Voriconazole in immunocompromised patients – single centre experience

Dorota Wójcik, Wojciech Pietras, Dorota Sęga-Pondel, Beata Celuch, Krzysztof Kałwak


<b>Background</b> Data on epidemiology and survival after fungal infections in patients with cancer are primarily based on studies in adults, whereas few data are available on children.
<b>Aim</b> The objective of this study was to determine the safety and tolerability of the
oral and i.v. formulations of voriconazole Vfend®, previously not reported in Poland.
<b>Materials/Methods</b> Twenty consecutive children and young adults aged 1 to 25 years, submitted for blood and marrow transplantation (BMT), were recruited during 10 months.
When suspected or verifi ed breakthrough systemic fungal infection occurred while kept on primary prophylactic fl uconazole regimen, all patients received two loading doses of i.v. or oral voriconazole 6–9 mg/kg every 12 hrs, followed by a maintenance dose of 3 mg/kg every 12 hrs for fi ve doses. If well tolerated, the voriconazole dosage was increased to 4 mg/kg every 12 hrs thereafter.
<b>Results</b> Fungal infection was possible in 15/20, organ involvement with pulmonary process in 13 pts; CNS changes in 2 pts. Fungal aetiology was proven in 3 children (pulmonary Aspergillosis in 2 and Candida krusei in 1 patient), and considered as
probable in 2 patients, having lung (2) and CNS (1) involvement. Four patients died. Clinical and radiological improvement was obtained in 14 patients, while uncontrolled, progressive disease occurred in 1 patient. Transient visual disturbances occurred in one patient. Major caution is warranted due to drug interaction via the cytochrome P-450 system which may lead to unexpected toxicity of the coadministered drugs (e.g. Vinca alkaloids, cyclosporine, rifampicin, erythromycin, etc).
<b>Conclusions</b> Voriconazole is an advantageous new azole well tolerated in 20 patients. Outcome in BMT breakthrough infections was good.

Signature: Rep Pract Oncol Radiother, 2007; 12(3) : 181-184


« back


Indexed in: EMBASE®, the Excerpta Medica database, the Elsevier BIOBASE (Current Awareness in Biological Sciences) and in the Index Copernicus.